BridgeBio Pharma, Inc. Quarterly Net Cash Provided by (Used in) Financing Activities in USD from Q1 2019 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
BridgeBio Pharma, Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from Q1 2019 to Q1 2024.
  • BridgeBio Pharma, Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $280M, a 86.1% increase year-over-year.
  • BridgeBio Pharma, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $452M.
  • BridgeBio Pharma, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was -$13.1M, a 102% decline from 2021.
  • BridgeBio Pharma, Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $736M, a 64.7% increase from 2020.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $280M +$129M +86.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-02
Q1 2023 $150M +$150M Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-02
Q1 2022 -$160K* -$548M Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-04
Q1 2021 $548M +$109M +24.8% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-05
Q1 2020 $439M +$441M Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-06
Q1 2019 -$1.65M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-14
* An asterisk sign (*) next to the value indicates that the value is likely invalid.